The AI-Native Pharmaceutical Pipeline: Technical Architectures and Economic Valuation The pharmaceutical industry faces a productivity crisis defined by Eroom’s Law, […]

A technically dense deep dive for pharma IP teams, R&D leads, and institutional investors, covering the full financing architecture, patent

Biologic Economics: Why These Drugs Cost This Much Biologics sit at the apex of pharmaceutical complexity. Unlike a small-molecule drug,

1. Executive Summary Drug development costs roughly double every nine years. That is Eroom’s Law, the inverse of Moore’s Law,

1. Why Excipient Switching Deserves a Seat at the Strategy Table {#1} Pharmaceutical companies spend millions optimizing the active pharmaceutical

I. Why Patent Landscaping Is a Core IP Asset, Not a Research Function Patent landscaping has a credibility problem in

1. The $2.6 Billion Bottleneck AI Is Supposed to Fix The standard number is $2.6 billion. That is the capitalized

The cheapest medicines in America are also the most dangerous ones to run out of. Generic sterile injectables — levofloxacin,

Every blockbuster drug carries two price tags: the $2.6 billion average cost of bringing it to market, and the cost